Loading...

FBIO FORTRESS BIOTECH INC US FDA Inspections 8-K Filing

FRTR

FB

FORTRESS BIOTECH INC

(FBIO)

2025 8-K

FDA Response Update

Financial Update

FDA Response Update

Financial Update

Regulatory Compliance

Appointed Directors

Merger of Equals

Earnings Releases

Management Change

Financial Results

Merger Agreement

FDA Action Delay

FDA Application Accepted

Financial Results

Financial Results

Credit Agreement and Warrants

Acquisition of Crystalys Th...

Bylaws Amendment

Annual Meeting Approval

Earnings Report

Financial Results Announcement

Departure of Director

Compliance and Program Tran...

Reverse Stock Split

Financial Results and Bylaw...

Departure of Directors or C...

Agreement to Lower Exercise...

Financial Results Announcement

Special Meeting of Stockhol...

Earnings Report

Investment Offering

External Links:

Cyprium Therapeutics, a subsidiary of Fortress Biotech, has had its New Drug Application for CUTX-101 delayed until September 30, 2025, while Sentynl Therapeutics takes over its development; Fortress retains rights to royalties and potential milestones of up to $129 million.

AI Assistant

FORTRESS BIOTECH INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.